|
|
|
| News |
|
May 25, 2007: Financial Results
HIGHLIGHTS: 1. Financial year 2006-07 Income by 22%, Net Profit up 91%. 2. Final Dividend of Rs.4/- per share (40%) recommended. Total dividend for financial year Rs.7.50 per share (75%). 3. 8 ANDA Applications of Formulations developed by the Company filed with USFDA. 2 ANDA applications approved. FINANCIAL RESULTS Ipca Laboratories Ltd. (Ipca) has posted improved financial results for the year ended 31st March, 2007. The total income for the year has gone up by 22% to Rs.921.24 crores as against Rs.752.82 crores in the previous financial year. Export Sales for the year increased by 21% to Rs.484.46 crores. The Net Profit for the financial year has increased by 91% to Rs.122.24 crores as against Rs.63.98 crores in the previous year. The Earning Per Share works out to Rs.48.89 per share of Rs.10/- each. The consolidated total income has increased by 24% to Rs.939.11 crores and the consolidated net profit has increased by 105% to Rs.126.17 crores. Consolidated Earnings per share works out to Rs.50.47 per share. The Board has recommended a final dividend of 40% (Rs.4 per share) for the financial year 2006-07. Together with the interim dividend of 35% already declared and paid, the total dividend for the financial year amounts to 75% (Rs.7.50 per share) as against 55% (Rs.5.50 per share) in the previous year. 4th
Quarter at a glance
2006-07 Audited Results at a glance
Ipca Laboratories is a backward integrated, fast growing pharmaceutical major, with a strong thrust on exports. Exports to over 110 countries, now account for 53% of Company's income.
Premchand
Godha Also see: Audited Financial Results.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||